Helix BioPharma (HBP) Stock Price, News & Analysis

Company Overview

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: C$0.97 to C$0.97
• 50-Day Range: C$0.57 to C$1.34
• 52-Week Range: C$0.50 to C$1.35
• Volume: N/A
• Average Volume: 5,875 shs
• Market Capitalization: C$47.55 million
• P/E Ratio: N/A
• Dividend Yield: 1.50%
• Price Target: N/A
• Consensus Rating: N/A

HBP Stock Analysis - Frequently Asked Questions

How have HBP shares performed this year?

Helix BioPharma's stock was trading at C$0.21 on January 1st, 2024. Since then, HBP shares have increased by 361.9% and is now trading at C$0.97.
View the best growth stocks for 2024 here.

How do I buy shares of Helix BioPharma?

Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Helix BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:HBP
• CUSIP: N/A
• CIK: N/A
• Web: www.helixbiopharma.com
• Phone: +1-416-9253232
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-6,140,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,220.62%
• Return on Assets: -279.98%

Debt

• Debt-to-Equity Ratio: 773.67
• Current Ratio: 0.74
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.09 per share
• Price / Cash Flow: 11.32
• Book Value: C($0.01) per share
• Price / Book: -97.00

Miscellaneous

• Outstanding Shares: 49,020,000
• Free Float: N/A
• Market Cap: C$47.55 million
• Optionable: Not Optionable
• Beta: -0.84